http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Valeritas Presents Positive h-Patch™ CBD Study Data as a Late-Breaking Presentation at the American Epilepsy Society 2019 Annual Meeting
-
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Reductions in A1c and Daily Insulin Usage
-
Valeritas Announces Third Quarter 2019 Financial Results
-
Valeritas Presents Positive h-Patch™ Apomorphine Study Data at the World Congress of Neurology (WCN 2019)
-
Valeritas to Report Third Quarter 2019 Financial Results on November 12, 2019
-
Valeritas (VLRX) Announces GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with its h-Patch Wearable Device in Preclinical Study
-
GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study
-
Valeritas Presents Positive h-Patch™ Apomorphine Study Data at Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia
-
Valeritas Announces Poster Presentation of Preclinical h-Patch™ Cannabidiol (CBD) Study at the American Epilepsy Society's Annual Meeting
-
Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the World Congress of Neurology (WCN 2019)
-
Valeritas Hosts Educational Symposium and Participates in the Metabolic & Endocrine Disease Summit (MEDS) East
-
Valeritas (VLRX) Reduces Long-Term Debt Obligation Nearly 60% by Exchanging $25M of Debt for Series B Convertible Preferred Stock
-
Valeritas Reduces its Long-Term Debt Obligation Nearly 60% by Exchanging $25.0 Million of Debt for Series B Convertible Preferred Stock
-
Valeritas Announces Participation on “The Cutting Edge of Cannabinoid Science” Panel at the CBD Expo EAST Conference
-
Valeritas Presents Positive h-Patch™ CBD Study Data at CannMed Conference
-
Valeritas Announces Presentation of Preclinical h-Patch™ CBD Study at CannMed Conference
-
Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia
-
Valeritas Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
-
Valeritas Announces Oral Presentation of Preclinical h-Patch™ CBD Study at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit
-
Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Valeritas (VLRX) Reports Clinical Trial Comparing Delivery of U-100 (RHI) vs. V-Go (RAI) in Type 2 Diabetes Patients Met Primary Endpoint
-
Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas’ V-Go® Meets Primary A1c Endpoint
-
Valeritas Announces Second Quarter 2019 Financial Results
-
Valeritas (VLRX) Reports Positive Results from Preclinical Pharmacokinetic Study of Apomorphine (Apo) Subcutaneous Infusion Delivered via h-Patch Device
-
Preclinical Study Shows Valeritas Proprietary h-Patch™ Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine
-
Valeritas Holdings (VLRX) Announces Positive Results from CBD Wearable Device PK Study
-
Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study
-
Valeritas to Report Second Quarter 2019 Financial Results on August 8, 2019
-
Valeritas (VLRX) announces positive data from retrospective study using HIRD comparing patients using V-Go to patients using MDI therapy
-
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population
-
Valeritas (VLRX) Reports Special FDA 510(K) Device Modification Submission to Include Use of RHI in V-Go Wearable Device
-
Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device
-
Valeritas Announces Milestone of 20 Million V-Go® Insulin Delivery Devices Sold
-
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 when Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery
-
Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Valeritas to Participate in the American Diabetes Association’s 79th Scientific Sessions; Company Reiterates Second Quarter and Full-Year 2019 Revenue Guidance
-
American Diabetes Association Includes “Disposable Patch-Like Device,” such as V-Go® from Valeritas, in the ADA Standards of Medical Care in Diabetes - 2019
-
Valeritas’ V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population
-
Valeritas (VLRX) Reports 1-for-20 Reverse Share Split
-
Valeritas Announces Reverse Stock Split
-
Valeritas Exhibits at Taking Control of Your Diabetes Conferences
-
Valeritas Announces First Quarter 2019 Financial Results and Updates Full Year 2019 Revenue Guidance
-
Valeritas Expects First Quarter Revenue of $6.4 million
-
Valeritas to Present at Upcoming Investor Conferences
-
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.5 and Total Daily Insulin Dosage by 14%
-
Valeritas to Report First Quarter 2019 Financial Results on May 9, 2019
-
Valeritas’ V-Go® Wearable Insulin Delivery Device Demonstrates 24% Reduction in Total Daily Insulin Dosage and Lower A1C Compared to Standard Insulin Treatment
-
Valeritas partners with the American Association of Diabetes Educators (AADE)
-
Valeritas Announces V-Go® Distribution Agreement in Israel
-
Valeritas to Present at the Oppenheimer 29th Annual Healthcare Conference
